摘要
目的:探讨对尿毒症贫血患者联合采用肾衰宁联合重组人促红细胞生成素(rhEPO)治疗的临床效果。方法:选取惠东县人民医院2021年4-9月收治的56例尿毒症贫血患者为研究对象,采用随机排列法分为对照组和观察组,各28例。两组均给予透析治疗,在治疗期间,对照组单纯给予rhEPO治疗,观察组给予rhEPO联合肾衰宁颗粒治疗,两组均持续治疗6周,比较治疗后两组炎症反应指标、贫血指标、营养指标和不良反应。结果:观察组治疗前炎症反应指标水平与对照组比较,差异无统计学意义(P>0.05);观察组治疗后炎症反应指标水平均低于对照组(P<0.05)。观察组治疗前贫血指标水平与对照组比较,差异无统计学意义(P>0.05);观察组治疗后贫血指标水平均高于对照组(P<0.05)。观察组治疗前营养指标水平与对照组比较,差异无统计学意义(P>0.05);观察组治疗后血清白蛋白(ALB)水平高于对照组,三酰甘油(TG)、总胆固醇(TC)、脂蛋白a[Lp(a)]和血肌酐(Scr)水平均低于对照组(P<0.05)。观察组不良反应总发生率与对照组比较,差异无统计学意义(P>0.05)。结论:对尿毒症贫血患者联合采用肾衰宁联合rhEPO治疗可以有效改善患者体内的微炎症状态,改善并纠正其贫血和营养不良状况,以延缓患者病情进展,保障患者透析治疗的安全性。
Objective:To discuss the clinical effects of Shenshuaining and recombinant human erythropoietin(rhEPO)in uremic anemia patients.Method:A total of 56 uremic anemia patients admitted to Huidong People’s Hospital from April to September 2021 were selected as the research objects.They were divided into control group and observation group with 28 cases in each group,according to random permutation method.Both groups were treated with the hemodialysis.During therapy period,the control group was treated with rhEPO,the observation group was treated with rhEPO and Shenshuaining Granules.After 6 weeks of treatment of two groups,the inflammatory factors,anemia states,nutritive index and adverse reactions were compared.Result:There were no significant differences between the observation group and the control group in the level of inflammatory response indexes before treatment(P>0.05).After treatment,the inflammatory response indexes in the observation group were lower than those in the control group(P<0.05).Before treatment,there were no significant differences between observation group and control group in the anemia indexes(P>0.05).After treatment,the anemia indexes in the observation group were higher than those in the control group(P<0.05).Before treatment,there were no significant differences between observation group and control group in the nutritional indexes(P>0.05).After treatment,serum albumin(ALB)value in the observation group was higher than that in the control group,triacylglycerol(TG),total cholesterol(TC),lipoprotein a[Lp(a)]and serum creatinine(Scr)levels in the observation group were lower than those in the control group(P<0.05).There was no significant difference between observation group and control group in overall adverse reaction rate(P>0.05).Conclusion:The combined treatment of Shenshuanin and rhEPO can effectively improve the micro-inflammatory state in uremic anemia patients,improve and correct their anemia and malnutrition,so as to delay the progression of patients and ensure the safety of hemodialysis treatment for patients.
作者
庄见钦
ZHUANG Jianqin(Huidong People’s Hospital,Huidong 516300,China)
出处
《中外医学研究》
2022年第10期4-8,共5页
CHINESE AND FOREIGN MEDICAL RESEARCH
基金
惠州市科技计划项目(2021WC0106047)。
关键词
尿毒症贫血
重组人促红细胞生成素
肾衰宁颗粒
炎性反应
营养指标
Uremic anemia
Recombinant human erythropoietin
Shenshuaining Granules
Inflammatory response
Nutritive index
